Teresa L. Young files SEC Form 4 disclosures for Seres Therapeutics, Inc.. They have made 1 open-market trade across 1 company since 2023, most recently 2026-02-15.
CIK 0001814656
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| MCRB | 8,632 | $18K |
Shares reported on the most recent Form 4, priced at the 2026-02-18 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MCRB | SELL | 2026-02-15 | 2026-02-18 | $8.47 | $635 | +8.9% | +2.7% | -9.1% |
| MCRB | SELL · 10b5-1 | 2025-11-15 | 2025-11-18 | $17.30 | $18K | -27.1% | -35.8% | -65.2% |
| MCRB | SELL · 10b5-1 | 2025-08-18 | 2025-08-19 | $16.65 | $982 | +16.3% | +10.7% | +32.9% |
| MCRB | SELL · 10b5-1 | 2025-05-16 | 2025-05-19 | $7.28 | $459 | -11.2% | -2.6% | +122.8% |
| MCRB | SELL · 10b5-1 | 2025-02-18 | 2025-02-19 | $0.81 | $3K | -8.7% | -13.2% | -49.8% |
| MCRB | SELL · 10b5-1 | 2024-11-18 | 2024-11-19 | $0.54 | $397 | +35.8% | +34.9% | +21.8% |
| MCRB | SELL · 10b5-1 | 2024-10-28 | 2024-10-29 | $0.69 | $2K | -5.4% | +29.7% | +11.4% |
| MCRB | SELL · 10b5-1 | 2024-08-16 | 2024-08-19 | $0.84 | $612 | -13.4% | +15.1% | -36.5% |
| MCRB | SELL · 10b5-1 | 2024-08-05 | 2024-08-06 | $1.08 | $26K | -12.9% | -10.9% | -20.0% |
| MCRB | SELL · 10b5-1 | 2024-05-15 | 2024-05-17 | $0.94 | $661 | +6.4% | -26.7% | -3.3% |
| MCRB | SELL · 10b5-1 | 2024-02-16 | 2024-02-16 | $1.08 | $4K | +5.6% | -29.8% | -14.4% |
| MCRB | SELL · 10b5-1 | 2023-10-30 | 2023-10-31 | $1.35 | $4K | -32.8% | -31.1% | -17.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.